GENs Top 10 Session Picks for the 2014 BIO International Convention

John Sterling | 05/01/2014

The following article, reproduced in full below, was originally published at Genetic Engineering & Biotechnology News.

Its been a hot year for biotech! As G. Steven Burrill, CEO of Burrill & Co., noted in a recent report, life science firms raised $2.9 billion in new equity capital globally from public investors in February. This included $1.1 billion raised by 18 companies that completed initial public offerings and $1.8 billion raised by 23 companies that completed follow-on offerings during the month.

In the U.S., 16 life sciences companies raised $959 million through IPOs and 22 companies raised $1.75 billion through follow-on offerings on U.S. exchanges during February, making the month the biggest for IPOs in terms of the number of completed deals since February 2000!

Why the excitement? Promising new biotherapeutics are emerging from the drug pipeline. Advances in stem cell research and regenerative medicine are occurring at a rapid pace. And OMICS technologies (e.g., genomics, proteomics, metabolomics, transcriptomics, glycomics, and lipomics), originally developed and used in the lab, are now making their way into clinical medicine, truly ready to usher in an era of personalized medicine.

The 2014 BIO International Convention will be held in San Diego this June. As usual, the BIO conference committee did a superb job in putting together a first-class program that covers a wide range of topics with something to offer everyone involved in biotech R&D or commercialization. Its been a tough call this year but here are my picks for the top 10 cant miss sessions at the conference.

To learn more about the program and available registration packages for Convention, please visithere

John Sterling is editor-in-chief of Genetic Engineering & Biotechnology News (GEN).

Read more:
GENs Top 10 Session Picks for the 2014 BIO International Convention